Objectives: Differentiating ulcerative colitis (UC) and Crohn disease (CD) can be clinically challenging, especially in children. Granulomatous inflammation has traditionally been attributed to CD. Crypt-associated giant cells and granulomas, however, have been observed in colonic biopsies of patients with UC. This phenomenon has not been described in the upper gastrointestinal (UGI) tract with UC. Methods: Seven pediatric patients with UC with granulomatous UGI (gUGI) lesions were identified. Diagnosis of UC was based on symptoms, clinical course, laboratory results, imaging, and endoscopy. We compared the gUGI patients to a large cohort of pediatric patients with UC (n ¼ 149). Results: All fully evaluated cases were associated with bloody diarrhea and moderate to severe pancolitis. Gastric and/or duodenal biopsies demonstrated giant cells or granulomas near gland destruction. Small bowel imaging did not reveal any involvement. The majority of cases responded to standard medical therapies, except for 2 patients (28.6%) who required total colectomy. Acute severe, refractory colitis (ie, colectomy within 1 month of presentation) was significantly more common in the gUGI group than the large pediatric UC group (28.6% vs 1.3%, Fisher exact P ¼ 0.01). Conclusions: This is the first report of pediatric UC-associated granulomatous inflammation in the UGI tract. We speculate that these lesions represent extracolonic manifestations of intense colonic disease. These atypical findings expand the diagnostic considerations that should be incorporated during the differentiation between UC and CD in the pediatric age group.
G iven considerable overlap in symptomatology and histology, differentiating ulcerative colitis (UC) and Crohn disease (CD) can be clinically challenging, especially in children. UC is classically defined as confluent and chronic intestinal mucosal inflammation of unknown etiology that is confined to the colon (1, 2) . Atypical features of UC have, however, been described that may cause diagnostic confusion, including upper gastrointestinal (UGI) involvement and granulomas (Table 1) (1) (2) (3) . Although granulomatous inflammation has traditionally been attributed to CD, isolated cases of crypt-associated giant cells and granulomas have been observed in colonic biopsies of patients with UC (1, 6) . This phenomenon has not yet been described in the UGI tract of patients with UC.
METHODS
We retrospectively identified 7 pediatric patients with histologic presence of granulomatous UGI (gUGI) lesions, whose inflammatory bowel disease (IBD) was consistent with UC on the basis of symptoms, physical examination, laboratory findings, imaging, endoscopy, and clinical course. More specifically, UC was characterized by diffuse, contiguous, chronic, and active inflammation (edema, erythema) of the colonic mucosa with or without ulceration, in the absence of small bowel disease, perianal disease, strictures, or fistulas. Patients with well-defined noncaseating granulomas without nearby cryptolysis were considered to have CD.
Other etiologies, such as infectious and medication-induced colitis, were excluded using a detailed history and the aforementioned clinical data (7) . The original diagnoses were not masked during secondary review of these cases. However, the final classification of IBD was based on expert opinion from gastroenterologists, radiologists, and pathologists upon thorough review of the medical
What Is Known
Nonclassic findings have been reported in patients with ulcerative colitis. Loosely formed granulomas and giant cells neighboring ruptured crypts have been described in colonic biopsies of patients with ulcerative colitis.
What Is New
Granulomatous changes can be found in the upper gastrointestinal tract of patients with ulcerative colitis. The presence of granulomatous inflammation may indicate a severe phenotype of ulcerative colitis. The identified gUGI cases were compared to a cohort of newly diagnosed pediatric patients with UC (n ¼ 149) who presented to TCH between 2003 and 2009, and whose clinical outcomes had been examined by our group (unpublished results: Ihekweazu FD, Fofanova T, Ajjarapu A, et al. Pediatric ulcerative colitis outcomes in the biologic era). We particularly evaluated for differences in rates of colectomy and biologic drug administration between the groups. Fisher exact test was used in the comparison of these 2 patient cohorts. Significance was set at P < 0.05.
RESULTS
All 7 cases (patients A-G) presented with bloody diarrhea. Each patient who underwent complete colonoscopy had moderate to severe pancolitis endoscopically (Table 2: C, E, F, and G). Extent of disease was not completely evaluated for patients B and D, because severe disease precluded the endoscopists from passing the splenic and hepatic flexures, respectively. Extent of colonic disease for patient A at time of diagnosis was unknown because endoscopy was performed at an outside facility and the report could not be obtained. However, the pathology slides of patient A were sent to our department for examination. Genetic testing was not performed in any of the patients. Patient G was the only patient who had Prometheus IBD Serology 7 testing, which demonstrated a predilection toward UC given elevated IBD-specific perinuclear antineutrophil cytoplasmic antibodies 36.4 EU/mL (reference <12.1 EU/mL). It is important to note that serology has been found to have low diagnostic value in children and is not routinely recommended for differentiating between IBD unclassified (IBDU) versus CD or UC (8) .
Upon review of the UGI biopsies, giant cells and/or granulomas were seen near gland destruction in all patients ( Fig. 1 ; see Supplemental Figs. 1 and 2, Supplemental Digital Contents 1 and 2, http://links.lww.com/MPG/B138, http://links.lww.com/MPG/B139, which demonstrate endoscopic and histologic findings of patients B, C, E, and F). Imaging did not reveal small bowel involvement outside of the duodenum in any of the patients (only patient A had duodenal friability and edema noted on pill endoscopy). The patients were followed for 1 to 6 years, during which time gross anatomic location of disease remained confined to the colon. Of note, crypt-associated granulomas and giant cells were observed in subsequent biopsies from patients B (colon) and E (stomach, duodenum) during clinical flare of their disease. Standard therapies were used with clinical improvement in the majority of cases (Table 2) . Patient A was later found to have autoimmune hepatitis with overlap of primary sclerosing cholangitis. Azathioprine and ursodiol were therefore added to her medication regimen, which included mesalamine and steroids. Patient C self-instituted the gut and psychology syndrome diet due to parental refusal of traditional pharmacotherapy and thus far has had an uncomplicated disease course.
Patients F and G required total colectomy within 1 month and 2 weeks of diagnosis, respectively. We found a trend toward an increased rate of colectomy in the gUGI UC patients compared to the larger UC cohort at 1-year follow-up (28.6% vs 6%, Fisher exact P ¼ 0.0783). With respect to our comparison group, the literature reports similar rates of 1-year colectomy among pediatric patients with UC (range 3.2%-6.5%) (8) (9) (10) . We also made comparisons to these published cohorts. There was a trend of increased colectomy at 1 year among our gUGI group when compared to 115 children with UC diagnosed at TCH between 1986 and 2003 (28.6% vs 4.1%, Fisher exact P ¼ 0.0519) (8) . Furthermore, there was a significantly higher rate of colectomy (28.6% vs 3.2%, Fisher exact P ¼ 0.0265) among our gUGI patients than a pediatric UC cohort in the United Kingdom (n ¼ 220, diagnosed between 1997 and 2014) (9) .
In alignment with the above findings, presentation with acute severe and medically refractory colitis (ie, colectomy within 1 month of presentation) was significantly more common in the gUGI patients than in our larger UC group (28.6% vs 1.3%, Fisher exact P ¼ 0.01). There was no difference in use of antitumor necrosis factor medication between the patients with UGI granulomatous inflammation and the larger UC cohort at 1-year follow-up (28.6% vs 8.1%, Fisher exact P ¼ 0.12). Since our sample size is small, it will be important to repeat these statistical analyses in larger cohorts.
DISCUSSION
IBD is recognized as a spectrum of diseases, including UC, CD, and IBDU. Patients with IBDU are characterized by UClike disease, but with subtle features suggestive of CD (11) . The prevalence of IBDU in children ranges from 4% to 29% in the pediatric literature (12) . Our study specifically aimed to address the diagnosis of IBDU to optimize differentiation of disease within this category. Such efforts can improve disease classification and guide medical management. This is the first report of pediatric UC-associated granulomatous inflammation observed in the UGI tract. A granuloma is defined as a collection of epithelioid histiocytes, which may include other cell types such as multinucleated giant cells or lymphocytes (1) . Granulomatous inflammation in pediatric patients with CD has been associated with more active and severe disease, and higher levels of C-reactive protein and mucosal microbiome separation at diagnosis (13, 14) . In CD, well-formed granulomas or isolated giant cells may be found in the lamina propria and are distant from epithelial injury (1) . In contrast, UC biopsies may demonstrate illdefined granulomas and giant cells that arise in response to extravasated mucin or fecal material released from epithelial crypt injury or surface erosion (1, 6) . Investigation of multiple tissue levels may be useful in establishing the relationship between granulomatous inflammation and damaged crypt epithelium (3).
In our study, all fully evaluated cases involved moderate to severe pancolitis. We speculate that the associated UGI granulomas and/or giant cells may be extracolonic manifestations of intense UC in response to epithelial cryptolysis. This conclusion is supported by significantly increased rates of acute severe, refractory colitis in the gUGI UC patients compared to a large group of pediatric UC cases. UGI granulomas and giant cells may therefore be markers of disease severity. In agreement with this conclusion, a recent study indicated that active inflammation in the UGI tract is associated with a higher likelihood of refractory behavior in pediatric UC patients (15) . Additional studies identifying gUGI inflammation in larger groups of pediatric patients with UC will help to further support these lesions as potential prognostic factors for UC.
Alternatively, UGI granulomatous inflammation related to crypt destruction may indicate an atypical UC phenotype. More specifically, these patients may represent a UC subclass with biologic susceptibility toward granulomatous inflammation. Indeed, extraintestinal giant cell-associated disease (particularly giant cell myocarditis) has been reported in some adult patients with concomitant UC (16) . In depth genetic investigations in the future may uncover heritable predisposition toward such complicated disease.
This case series highlights the importance of considering the diagnosis of UC in patients even with granulomatous inflammation in upper GI tract biopsies in the vicinity of mucosal gland destruction. Our observations further the challenge of differentiating UC and CD in the pediatric age group. Awareness of these atypical UC manifestations is important to prevent misdiagnosis and to guide appropriate management.
